Detalhe da pesquisa
1.
Aprotinin treatment against SARS-CoV-2: A randomized phase III study to evaluate the safety and efficacy of a pan-protease inhibitor for moderate COVID-19.
Eur J Clin Invest
; 52(6): e13776, 2022 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-35342931